| Drug Type Fusion protein | 
| Synonyms CD16-IL15-HERC2 TriKE, HERC2-TriKE (GT Biopharma) | 
| Target | 
| Action agonists, modulators | 
| Mechanism FcRIII agonists(Low affinity immunoglobulin gamma Fc region receptor III agonists), HERC2 modulators(HECT and RLD domain containing E3 ubiquitin protein ligase 2 modulators), IL-15Rα agonists(Interleukin-15 receptor subunit alpha agonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhaseDiscovery | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Solid tumor | Discovery | United States  | - | 






